Engineered nutrient-stimulated hormonal multi-agonist for precision targeting of obesity and metabolic disorders

Nov 26, 2025Clinical and molecular hepatology

Designed nutrient-based hormone activator for targeted treatment of obesity and metabolism problems

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Tirzepatide, a GLP-1/GIP dual agonist, has achieved unprecedented levels of weight loss and glycemic improvement.

Obesity and related metabolic disorders are increasingly recognized as complex, multifaceted conditions.
GLP-1 receptor agonists (GLP-1RAs) have shown significant benefits in managing glycemic control and weight loss.
Limitations of GLP-1RAs have led to the development of engineered multi-agonist therapies targeting additional hormonal pathways.
Dual and triple peptide-based agonists have demonstrated superior metabolic efficacy in both preclinical and clinical studies.
Certain multi-agonist agents may offer additional benefits for liver, cardiovascular health, and inflammation.
Non-peptidyl oral GLP-1RAs present new strategies to improve treatment accessibility and adherence.

AI simplified

Obesity and its related metabolic comorbidities, including type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, and cardiovascular disease, are increasingly recognized as heterogeneous and multisystemic disorders. Despite the significant benefits in glycemic control and weight loss exhibited by GLP-1 receptor agonists (GLP-1RAs), their limitations have initiated the development of engineered multi-agonist therapies targeting additional nutrient-stimulated hormonal (NUSH) pathways. Dual and triple peptide-based co-agonists combining glucagon-like peptide-1 (GLP-1) with glucose-dependent insulinotropic polypeptide (GIP), glucagon, amylin, or peptide YY have demonstrated superior metabolic efficacy in preclinical and clinical studies. Tirzepatide (GLP-1/GIP dual agonist), CagriSema (GLP-1/amylin dual agonist), and retatrutide (GLP-1/GIP/glucagon triple agonist) have achieved unprecedented levels of weight loss and glycemic improvement, with certain agents also demonstrating hepatic, cardiovascular, and inflammatory benefits. Non-peptidyl oral GLP-1RAs, such as orforglipron, offer novel formulation strategies to enhance treatment accessibility and adherence. Multi-agonist incretin-based therapies represent a paradigm shift in the management of obesity and metabolic diseases. These agents offer broad clinical utility beyond glucose lowering by mimicking the pleiotropic hormonal responses observed after bariatric surgery. These therapies are poised to emerge as key components of precision metabolic medicine. This review article explores the mechanistic basis, pharmacological characteristics, and clinical data supporting the use of engineered NUSH-based peptide therapies for obesity and its related metabolic disorders, with particular emphasis on recent progress in the development and clinical application of dual and triple agonists.

Full Text

Full text is available at the source.

View full text ↗

Engineered nutrient-stimulated hormonal multi-agonist for precision targeting of obesity and metabolic disorders

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief